Table 2.

Unadjusted and adjusted odd ratios for clinical remission at M6 and last follow-up of baseline indicators (M0)

UnadjustedAdjusted
EffectOdds Ratio95% Wald Confidence LimitsType 3 Analysis P ValueOdds Ratio95% Wald Confidence LimitsType 3 Analysis P Value
M6
 Age, yr1.020.981.070.381.020.971.070.37
 Sex0.930.96
  Men11
  Women0.940.253.531.040.244.54
 PLA2R1-Ab at M0, RU/ml1.000.991.000.671.000.991.000.44
 Treatment0.370.21
  NIAT11
  NIAT and RITUX1.730.525.692.370.629.06
 Spreading M00.020.02
  No11
  Yes 0.230.070.790.160.040.72
Last follow-up
 Age, yr1.010.981.050.511.020.981.070.38
 Sex
  Men10.9210.54
  Women1.060.333.391.540.45.99
 PLA2R1-Ab at M0, RU/ml1.000.991.000.221.000.991.000.86
 Treatment
  NIAT10.1210.04
  NIAT and RITUX2.340.816.743.721.0513.2
 Spreading M0
  No10.0110.01
  Yes 0.180.050.650.150.030.64
  • Note that spreading at baseline is the only predictor of remission at M6, and it also predicts remission at last follow-up before any treatment modification, independently from PLA2R1-Ab titer.